Spoken Alpha
NOMAD POWER SOLUTIONS, INC.
Lixte Biotechnology Holdings, Inc. develops cancer therapies and proton therapy systems. The company's lead drug candidate, LB-100, is a protein phosphatase 2A inhibitor in clinical trials for ovarian cancer, colorectal cancer, and soft tissue sarcoma, designed to enhance the effectiveness of chemotherapy and immunotherapy.
NOMAD POWER SOLUTIONS, INC is a Industrials company operating in Electrical Equipment & Parts with a $125.4M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 5, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add LIXT, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LIXT.
$ curl https://api.spokenalpha.com/v1/companies/LIXTFAQ
Spoken Alpha indexes LIXT's earnings call transcripts at https://spokenalpha.com/companies/LIXT. Each call links to attributed speakers and parsed analyst Q&A. NOMAD POWER SOLUTIONS, INC.'s own investor relations page is at https://ir.lixte.com/.
NOMAD POWER SOLUTIONS, INC. (LIXT) operates in the Industrials sector (Electrical Equipment & Parts industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | — | — | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-03-30 | $-0.18 | — | — | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-0.33 | — | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.33 | — | — | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.29 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.29 | — | — | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-16 | $-0.27 | — | — | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.44 | — | — | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.45 | — | — | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.43 | — | — | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-18 | $-0.46 | — | — | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.49 | — | — | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-08 | $-1.00 | — | — | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-09 | $-0.08 | — | — | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-28 | $-0.10 | — | — | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $-0.09 | — | — | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-09 | $-0.10 | — | — | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-0.12 | — | — | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-20 | $-0.15 | — | — | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.09 | — | — | $0 | — | — | EODHD |
Source: EODHD. LIXT reported actuals as published; sparse fields render as —.